SCHEMBL131896

SCHEMBL131896

CC(=O)NN=C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909119 0.80 MAPT (0.44)
SCHEMBL1691078 0.78
SCHEMBL8885932 0.75
SCHEMBL21300755 0.75
SCHEMBL8885935 0.75
SCHEMBL24136136 0.75
SCHEMBL20323218 0.75 CTH (0.44)
SCHEMBL22297104 0.75
SCHEMBL22504890 0.75
SCHEMBL11103172 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 710 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103923765-A Detergent Composition For Process Of Manufacturing Semiconductors And Displays COWON INNOTECH INC 2014-07-16 CN claimed
US-20240240182-A1 HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF BANK OF AMERICA, N.A. 2024-07-18 US disclosed
US-20240240182-A1 HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF BANK OF AMERICA, N.A. 2024-07-18 US disclosed
US-20240218366-A1 COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF BANK OF AMERICA, N.A. 2024-07-04 US disclosed
US-20240209373-A1 ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF ALNYLAM PHARMACEUTICALS, INC. (US) 2024-06-27 US disclosed
US-20240209372-A1 PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF BANK OF AMERICA, N.A. 2024-06-27 US disclosed
US-20240209369-A1 COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF BANK OF AMERICA, N.A. 2024-06-27 US disclosed
US-20240209372-A1 PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF BANK OF AMERICA, N.A. 2024-06-27 US disclosed
US-12018260-B2 Tunable Reversir™ compounds ALNYLAM PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
US-12018260-B2 Tunable Reversir™ compounds ALNYLAM PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
WO-2009082606-A2 FOLATE CONJUGATES ALNYLAM PHARMACEUTICALS, INC. (US) 2009-07-02 WO disclosed
WO-2009082607-A2 TARGETING LIPIDS ALNYLAM PHARMACEUTICALS, INC. (US) 2009-07-02 WO disclosed
WO-2009073809-A2 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2009-06-11 WO disclosed
EP-2066688-A2 MACROCYCLIC HCV INHIBITORS AND THEIR USES Novartis AG (CH) 2009-06-10 EP disclosed
US-20090118284-A1 Novel compounds that are ERK inhibitors MERCK SHARP & DOHME LLC 2009-05-07 US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 US disclosed
WO-2008033389-A2 MACROCYCLIC HCV INHIBITORS AND THEIR USES NOVARTIS AG (CH) 2008-03-20 WO disclosed
WO-2008033389-A2 MACROCYCLIC HCV INHIBITORS AND THEIR USES NOVARTIS AG (CH) 2008-03-20 WO disclosed
US-20070191604-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-08-16 US disclosed